Belvedere Trading
ALDX icon

Belvedere Trading’s Aldeyra Therapeutics ALDX Stock Holding History

Belvedere Trading’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-900
Closed -$7.55K – 631
2023
Q2 		$7.55K Sell
900
-12,000
-93% -$118K ﹤0.01% 731
2023
Q1 		$128K Buy
+12,900
New +$91.2K ﹤0.01% 420
2022
Q3 		– Sell
-23,400
Closed -$118K – 265
2022
Q2 		$118K Buy
+23,400
New +$80.5K ﹤0.01% 238

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Belvedere Trading's ALDX Position: Q3 2023 in Review

Belvedere Trading sold out of Aldeyra Therapeutics (ALDX) in Q3 2023, closing a stake of 5,956 shares — an estimated $50K sold.

Belvedere Trading first reported a position in ALDX in Q1 2021 and held it in 6 quarters. The position peaked at $249K in Q1 2023. 120 funds tracked by Wall St. Rank hold ALDX as of Q3 2023.

  • Belvedere Trading reported no remaining Aldeyra Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Belvedere Trading sold 5,956 Aldeyra Therapeutics shares in Q3 2023, an estimated $50K.
  • Belvedere Trading first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 6 quarters.
  • Belvedere Trading's Aldeyra Therapeutics position peaked at $249K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.